Yasuhiro Choda

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Li‐Tzong Chen, Min‐Hee Ryu et al. · The Lancet Oncology · 2022 · 712 citations · Full text

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Sun Young Rha, Do‐Youn Oh, Patricio Yañez et al. · The Lancet Oncology · 2023 · 521 citations

Chemotherapy Versus Placebo, Gastrointestinal Oncology, Medicine +8

A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in advanced gastrointestinal cancer patients with cancer cachexia

Satoshi Hamauchi, Junji Furuse, Toshimi Takano et al. · Cancer · 2019 · 157 citations · Full text

Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial

Takaki Yoshikawa, Masanori Terashima, Junki Mizusawa et al. · ˜The œLancet. Gastroenterology & hepatology · 2019 · 109 citations

Oncology, Esophageal Cancer, Gastrointestinal Oncology +7

Multicenter retrospective study to evaluate the efficacy and safety of the double‐flap technique as antireflux esophagogastrostomy after proximal gastrectomy (<scp>rD</scp>‐<scp>FLAP</scp> Study)

Shinji Kuroda, Yasuhiro Choda, S. Otsuka et al. · Annals of Gastroenterological Surgery · 2018 · 103 citations · Full text